We are live on ! Find out more
PCRX icon

Pacira BioSciences
PCRX

273 hedge funds and large institutions have $2.67B invested in Pacira BioSciences in 2022 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 116 increasing their positions, 83 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

40% more repeat investments, than reductions

Existing positions increased: 116 | Existing positions reduced: 83

1.84% more ownership

Funds ownership: 107.74% → 109.57% (+1.8%)

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

4% less funds holding

Funds holding: 284 → 273 (-11)

5% less capital invested

Capital invested by funds: $2.82B → $2.67B (-$150M)

27% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 30

43% less call options, than puts

Call options by funds: $3.31M | Put options by funds: $5.79M

Holders
273
Holders Change
-11
Holders Change %
-3.87%
% of All Funds
4.7%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
22
Increased
116
Reduced
83
Closed
30
Calls
$3.31M
Puts
$5.79M
Net Calls
-$2.48M
Net Calls Change
+$10.2M

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$55.6M
2
Millennium Management
Millennium Management
New York
+$24.3M
3
Jennison Associates
Jennison Associates
New York
+$21.3M
4
VOYA Investment Management
VOYA Investment Management
Georgia
+$13.3M
5
Wellington Management Group
Wellington Management Group
Massachusetts
+$11.9M

Top Sellers

Rank Fund Capital Flow
1
Macquarie Group
Macquarie Group
Australia
-$35M
2
PC
Paulson & Co
New York
-$20.4M
3
Renaissance Technologies
Renaissance Technologies
New York
-$11.8M
4
SCM
Spyglass Capital Management
California
-$11.6M
5
GLA
Great Lakes Advisors
Illinois
-$8.93M
Name Holding Trade Value Shares
Change 		Change in
Stake
BNP Paribas Financial Markets
276
BNP Paribas Financial Markets
France
– -$711K -12,194 Closed
QC
277
Quantedge Capital
Singapore
– -$635K -10,900 Closed
PCM
278
Prelude Capital Management
New York
– -$573K -9,837 Closed
ETC
279
Exchange Traded Concepts
Oklahoma
– -$545K -9,355 Closed
GCM
280
Graham Capital Management
Connecticut
– -$317K -5,446 Closed
TI
281
Trexquant Investment
Connecticut
– -$272K -4,662 Closed
VI
282
Versor Investments
New York
– -$245K -4,200 Closed
NCM
283
Next Capital Management
New York
– -$204K -3,503 Closed
DWM
284
Dakota Wealth Management
Florida
– -$202K -3,460 Closed
PHK
285
Point72 Hong Kong
Hong Kong
– -$46K -788 Closed
NICM
286
Neo Ivy Capital Management
New York
– -$44K -757 Closed
AS
287
Altshuler Shaham
Israel
– -$27K -469 Closed
CCA
288
Column Capital Advisors
Indiana
– -$20K -349 Closed
MGI
289
MayTech Global Investments
New York
– -$17K -300 Closed
EC
290
Elequin Capital
New York
– -$12K -212 Closed
CG
291
Cutler Group
California
– -$5K -100 Closed
DFCM
292
Dark Forest Capital Management
Puerto Rico
– -$890 -16 -94%
Northwestern Mutual Wealth Management
293
Northwestern Mutual Wealth Management
Wisconsin
– -$1K -16 Closed
JWA
294
JFS Wealth Advisors
Pennsylvania
– -$222 -4 -33%
C
295
Covestor
United Kingdom
– -$111 -2 -33%
DI
296
Disciplined Investments
Oklahoma
– -$56 -1 -25%
PA
297
Parallel Advisors
California
– -$56 -1 -33%
HNB
298
Huntington National Bank
Ohio
– +$56 +1 +9%
GWS
299
Glassman Wealth Services
Virginia
– +$167 +3 New
SIC
300
SJS Investment Consulting
Ohio
– +$222 +4 New
9 10 11
12
13

PCRX Hedge Fund Activity: Q3 2022 in Review

273 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q3 2022, worth a combined $2.67B — down 5.3% from $2.82B a quarter earlier.

Sellers outnumbered buyers: 30 funds closed out of PCRX and 22 opened new positions — a net loss of 8 holders — while 83 trimmed existing stakes and 116 added.

The largest buyer was Armistice Capital, adding an estimated $55.6M. The largest seller was Macquarie Group, cutting an estimated $35M.

  • 273 institutional investors held Pacira BioSciences (PCRX) as of Q3 2022, down from 284 in Q2 2022.
  • Funds reported $2.67B of Pacira BioSciences stock for Q3 2022, down 5.3% quarter-over-quarter.
  • 22 funds opened new Pacira BioSciences positions in Q3 2022 and 30 closed out, a net change of -8 holders.
  • The largest Pacira BioSciences buyer in Q3 2022 was Armistice Capital, an estimated $55.6M added.
  • The largest Pacira BioSciences seller in Q3 2022 was Macquarie Group, an estimated $35M sold.

Based on aggregated 13F filings for Q3 2022.